Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

Trial Identifier: D9230C00003
Sponsor: AstraZeneca
NCTID:: NCT05560607
Start Date: August 2022
Primary Completion Date: January 2023
Study Completion Date: January 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, TX San Antonio, TX, US, 78215